金石亚药(300434) - 2025 Q3 - 季度业绩预告

Sichuan Jinshi Asia Pharmaceutical Co., Ltd. 2025 Q1-Q3 Performance Forecast I. Current Period Performance Forecast The company projects 2025 Q1-Q3 net profit to increase 48.99%-83.95%, reaching 86.61 million to 106.93 million yuan - The performance forecast period is from January 1, 2025, to September 30, 2025, with net profit expected to be positive and increase year-on-year[3] Key Financial Data for 2025 Q1-Q3 Performance Forecast | Indicator | Estimated Amount for Current Period (million yuan) | Year-on-Year Growth | Actual Amount for Same Period Last Year (million yuan) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 86.6055 — 106.9263 | 48.99% — 83.95% | 58.1291 | | Net Profit After Deducting Non-Recurring Gains/Losses | 69.1279 — 89.4488 | 32.83% — 71.88% | 52.0414 | II. Communication with Accounting Firm The performance forecast data is a preliminary estimate by the finance department and is unaudited by an accounting firm - The data related to this performance forecast has not been audited by an accounting firm[5] III. Explanation of Performance Changes Performance growth is attributed to budget optimization, lower period expenses, improved new materials and machinery business from R&D commercialization, and positive non-recurring gains - Through budget optimization and expense control, the company achieved a year-on-year decrease in period expenses, ensuring stable business development[6] - The new materials and machinery business segment saw year-on-year improvements in revenue and gross profit due to the successful commercialization of prior R&D projects[6] - During the reporting period, non-recurring gains and losses are expected to impact net profit by approximately 17.4776 million yuan[6] IV. Other Related Explanations This performance forecast is a preliminary estimate, with detailed data in the 2025 Q3 report; investors are advised to note investment risks - This performance forecast is a preliminary estimate by the company's finance department, with specific data to be detailed in the 2025 Q3 report[7] - Investors are advised to make cautious decisions and be aware of investment risks[7] V. Documents for Reference The board of directors' explanatory statement on the 2025 Q1-Q3 performance forecast serves as a reference document - Documents for reference include the board of directors' explanatory statement on the 2025 Q1-Q3 performance forecast[8]